FER1L4 Pseudogene: A New Biomarker for Melanoma
Author Information
Author(s): Kolenda Tomasz, Guglas Kacper, Stasiak Maciej, Poter Paulina, Kozlowska-Maslon Joanna, Bialas Piotr, Sobocinska Joanna, Janiczek-Polewska Marlena, Mantaj Patrycja, Paszkowska Anna, Cybulski Zefiryn, Teresiak Anna, Kazimierczak Urszula, Przybyla Anna, Mackiewicz Andrzej, Mackiewicz Jacek
Primary Institution: Greater Poland Cancer Center
Hypothesis
The FER1L4 pseudogene may serve as a diagnostic and prognostic biomarker for cutaneous melanoma.
Conclusion
Higher expression levels of the FER1L4 pseudogene are associated with improved survival rates in melanoma patients.
Supporting Evidence
- FER1L4 expression was significantly higher in melanoma cells compared to normal melanocytes.
- Higher FER1L4 levels were associated with improved patient survival.
- FER1L4 expression was influenced by BRAF mutations.
- Patients with elevated FER1L4 levels exhibited distinct phenotypes and altered immune profiles.
- Significant differences in FER1L4 expression were observed between primary and metastatic melanoma samples.
Takeaway
This study found that a specific gene called FER1L4 can help doctors understand how melanoma works and predict how well patients will do.
Methodology
The study analyzed FER1L4 expression in melanoma cell lines and patient samples using qRT-PCR and TCGA data.
Participant Demographics
The study included 472 melanoma patients with various clinicopathological features.
Statistical Information
P-Value
p = 0.0034
Confidence Interval
95 % CI = 0.6044 to 0.9484
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website